Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
The Journal of Thoracic and Cardiovascular Surgery
|
March 7, 2006
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma
D Lardinois, F J Jung, I Opitz, et al.
Pathology, Research and Practice
|
July 6, 2023
Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches
G Treichler, S Hoeller, J H Rueschoff, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 23, 2020
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug
R A Stahel, A Curioni-Fontecedro, S Rohrmann, et al.
EJNMMI Research
|
July 15, 2020
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
M Pavic, M Bogowicz, J Kraft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial
S Hiltbrunner, C Britschgi, P Schuberth, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
The Journal of Thoracic and Cardiovascular Surgery
|
March 7, 2006
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma
D Lardinois, F J Jung, I Opitz, et al.
Pathology, Research and Practice
|
July 6, 2023
Improving the turnaround time of molecular profiling for advanced non-small cell lung cancer: Outcome of a new algorithm integrating multiple approaches
G Treichler, S Hoeller, J H Rueschoff, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 23, 2020
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug
R A Stahel, A Curioni-Fontecedro, S Rohrmann, et al.
EJNMMI Research
|
July 15, 2020
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients
M Pavic, M Bogowicz, J Kraft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2020
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial
S Hiltbrunner, C Britschgi, P Schuberth, et al.
ESMO Open
|
November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
L Frehner, S Schär, S Hayoz, et al.
ESMO Open
|
April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]
D König, S Schär, D Vuong, et al.
ESMO Open
|
April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
D König, S Schär, D Vuong, et al.
ESMO Open
|
July 13, 2023
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D König, S Savic Prince, S Hayoz, et al.
Page
of 3